Leveraging vaccine policy and investments for the AMR challenge
In this commentary, we reflect on GAVI's experience incorporating an antimicrobial resistance (AMR) criterion into the Vaccine Investment Strategy to explore how global vaccine policy can more integrate AMR objectives, and identify priority actions for maximizing the AMR impact of vaccines. This article is part of the Royal Society Science+ meeting issue 'Vaccines and antimicrobial resistance: from science to policy'.
Authors
- Nidhee Jadeja (ORCID: https://orcid.org/0000-0001-7636-233X)
- Birgitte Giersing (ORCID: https://orcid.org/0000-0003-2555-7756)
- Maya Malarski
- Mateusz Hasso-Agopsowicz
- Marta Urrutxi Gallastegi
- Marta Tufet
- Michelle Jimenez
Institutions
- World Health Organization - Pakistan (PK)
- Gavi (CH)
Publication Details
- Journal
- Philosophical Transactions of the Royal Society B Biological Sciences
- Published
- 2026-02-19
- DOI
- https://doi.org/10.1098/rstb.2025.0010
- Citations
- 1
- Primary Topic
- Antibiotic Use and Resistance
- Type
- article
- Field-Weighted Citation Impact
- 53.52
Funders
- UK Research and Innovation
- Department of Health and Social Care
- Medical Research Council